Fig. 2
Multimodal 3D imaging with MALDI MSI, MRI and H&E, letters ‘L’ and ‘R’ denote left and right sides of the mouse brain. a contrast-enhanced T1-weighted MR image of mouse with established intracranial tumor. b MALDI MS imaging of serial coronal sections of mouse brain (subset from tumor core only displayed, see Supplementary Figure 2 for full set of images) with established GBM tumor after treatment with 100 mg kg−1 erlotinib (2 h post-dose) with corresponding H&E staining of adjacent sections (ion images of erlotinib (green, m/z 394.176 ± 0.001) and heme (red, m/z 616.177 ± 0.001) overlaid, c 3D reconstructions of MALDI ion images collected at 160 μm intervals and imaged at 100 μm spatial resolution, Erlotinib (green, m/z 394.176 ± 0.001), heme (red, m/z 616.177 ± 0.001), the active metabolite of erlotinib (M13/M14) (cyan, m/z 380.160 ± 0.001), and a tumor biomarker (white, m/z 503.949 ± 0.001), d automatic multimodal non-rigid alignment of erlotinib ion image with T2W and T1Gd MR images of one example section/plane, and regions of interest (ROI) mask image for normal brain (1), tumor associated drug exclusive of T1Gd hyperintensity (2), and T1Gd hyper intensity (3) were generated from the registered T1Gd MR and erlotinib ion images, and e boxplot of erlotinib intensity detected in each ROI, where the center line represents the median, the upper and lower bounds of the box represent the inter-quartile range and the whiskers represent ±1 standard deviation of the mean
